UNSPSC 51301904: Griseofulvin

This classification denotes an anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 32HRV3E3D5. European Medicines Agency schedules Griseofulvin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07966MIG. Griseofulvin generally arises in the molecular formula C17H17CLO6. The term GRISEOFULVIN is an International Non-Proprietary Name or INN. GRISEOFULVIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule griseofulvin under HS 29419000 and SITC 54139. As of Q4 2014, GRISEOFULVIN remains the US FDA Preferred Term for this commodity. Griseofulvin bears US NLM identifiers UMLS ID C0018242 and NCI Concept Code C65819. SMILES: CLC1C2OC3(C(CC(=O)C=C3OC)C)C(=O)C2C(OC)CC1OC.

UNSPSC 51301904 Griseofulvin is a Commodity code that shows little relevant recent activity under its nominal scope. The most recent opportunities posted under this code are for liquid aluminum sulfate (alum) used in municipal wastewater treatment and medical aid supplies for fire rescue departments — neither of which aligns with griseofulvin, an antifungal pharmaceutical. The code appears to be either misapplied to these procurements or represents a data-tagging anomaly rather than a deliberate targeting of the pharmaceutical itself.

The City of Austin issued IFB 2200 CSH1061 in July 2026 for liquid aluminum sulfate delivery to its wastewater treatment facility with a response deadline of August 25, 2026, while the City of Tampa Fire Rescue Department posted ITB 25-P-00157 in April 2026 for a broad array of medical and first aid supplies with an April 9, 2025 response date. Neither procurement aligns with antifungal medications or pharmaceutical distribution. State and local procurement professionals should treat this code with caution — verify the actual commodity or service under consideration before pursuing, as the tagged opportunities do not support a clear market signal for griseofulvin procurement activity.